Medindia

X

Scientists Uncover Key Protein for Tumor Suppression in ER+ Breast Cancer

by Rajashri on  July 16, 2009 at 8:53 PM Cancer News   - G J E 4
 Scientists Uncover Key Protein for Tumor Suppression in ER+ Breast Cancer
A protein relationship that may be an ideal treatment target for ER+ breast cancer has been identified by researchers from the Kimmel Cancer Center at Jefferson. The study was reported in the July 15 issue of Cancer Research.
Advertisement

DACH1, a cell fate determination factor protein, prevents cancer cell proliferation by repressing the function of estrogen receptorsin breast cancer, the researchers found. However, they also found that as the presence of DACH1 decreases in breast cancer, the presence of estrogen receptors increases, and vice versa.

Advertisement
Approximately 70% of breast cancers are ER+. Treatment for ER+ breast cancer usually consists of hormone therapy, which includes lowering the natural estrogen levels in the body or using synthetic drugs like tamoxifen, which compete with natural estrogen. However, this treatment only works for a few years.

"Eventually, cancer cells will circumvent the estrogen-dependent growth and find a different pathway through which they will proliferate," said Vladimir Popov, a doctoral student in Biochemistry and Molecular Biology at Jefferson College of Graduate Studies of Thomas Jefferson University and the study's first author. "Our lab has shown that there is a correlation between DACH1 and estrogen receptors. DACH1 is a naturally occurring repressor of estrogen receptor function in normal breast tissue, which makes it a promising therapeutic target for patients with ER+ breast cancer."

DACH1 is expressed in normal breast tissue. As breast cancer develops and becomes more invasive, the expression of DACH1 decreases. In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis. Patients who did express DACH1 lived an average of 40 months longer.

"Many more studies need to be done, but there is strong evidence that DACH1 is a promising marker of survival and therapeutic target in patients with breast cancer," said the study's senior researcher Richard Pestell, M.D., Ph.D, who is director of the Kimmel Cancer Center and chair of the Cancer Biology department at Jefferson.



Source: Eurekalert
RAS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All